 MONMOUTH JUNCTION, N.J., Oct. 7, 2021 PRNewswire -- CytoSorbents Corporation NASDAQ: CTSO, a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification, announced the public availability of preliminary data abstracts from two separate endocarditis studies, including the REMOVE study, to be presented at the upcoming European Association for Cardio-Thoracic Surgery EACTS annual meeting taking place in Barcelona, Spain from October 13-16, 2021, where more extensive data are expected to be made available. 